HUP9904026A3 - Use of sibutramine analogues to prevent the development of diabetes - Google Patents

Use of sibutramine analogues to prevent the development of diabetes

Info

Publication number
HUP9904026A3
HUP9904026A3 HU9904026A HUP9904026A HUP9904026A3 HU P9904026 A3 HUP9904026 A3 HU P9904026A3 HU 9904026 A HU9904026 A HU 9904026A HU P9904026 A HUP9904026 A HU P9904026A HU P9904026 A3 HUP9904026 A3 HU P9904026A3
Authority
HU
Hungary
Prior art keywords
diabetes
development
prevent
sibutramine
analogues
Prior art date
Application number
HU9904026A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of HUP9904026A2 publication Critical patent/HUP9904026A2/hu
Publication of HUP9904026A3 publication Critical patent/HUP9904026A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
HU9904026A 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes HUP9904026A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process

Publications (2)

Publication Number Publication Date
HUP9904026A2 HUP9904026A2 (hu) 2000-05-28
HUP9904026A3 true HUP9904026A3 (en) 2000-07-28

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904026A HUP9904026A3 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Country Status (26)

Country Link
US (3) US6174925B1 (cg-RX-API-DMAC10.html)
EP (1) EP0927028A1 (cg-RX-API-DMAC10.html)
JP (1) JP2001503737A (cg-RX-API-DMAC10.html)
KR (1) KR20000048501A (cg-RX-API-DMAC10.html)
CN (1) CN1237905A (cg-RX-API-DMAC10.html)
AU (1) AU724488B2 (cg-RX-API-DMAC10.html)
BG (1) BG64473B1 (cg-RX-API-DMAC10.html)
BR (1) BR9711517A (cg-RX-API-DMAC10.html)
CA (1) CA2266401C (cg-RX-API-DMAC10.html)
CZ (1) CZ93699A3 (cg-RX-API-DMAC10.html)
GB (1) GB9619757D0 (cg-RX-API-DMAC10.html)
HR (1) HRP970505A2 (cg-RX-API-DMAC10.html)
HU (1) HUP9904026A3 (cg-RX-API-DMAC10.html)
ID (1) ID18320A (cg-RX-API-DMAC10.html)
IL (1) IL128850A (cg-RX-API-DMAC10.html)
MY (1) MY116150A (cg-RX-API-DMAC10.html)
NO (1) NO991358L (cg-RX-API-DMAC10.html)
NZ (1) NZ334580A (cg-RX-API-DMAC10.html)
PL (1) PL332305A1 (cg-RX-API-DMAC10.html)
RU (1) RU2245709C2 (cg-RX-API-DMAC10.html)
SK (1) SK31999A3 (cg-RX-API-DMAC10.html)
TR (1) TR199900618T2 (cg-RX-API-DMAC10.html)
TW (1) TW580385B (cg-RX-API-DMAC10.html)
UA (1) UA64726C2 (cg-RX-API-DMAC10.html)
WO (1) WO1998011884A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA978450B (cg-RX-API-DMAC10.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
EP1093370B1 (en) * 1998-06-30 2006-02-22 Takeda Pharmaceutical Company Limited Pharmaceutical composition for the treatment of diabetes
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
MXPA01012494A (es) 1999-06-01 2002-07-02 Univ Texas Southwestern Med Ct Metodo para tratar perdida capilar con el uso de compuestos sulfonil tiromimeticos.
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
MXPA05003355A (es) * 2002-10-05 2005-10-18 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende semihidrato de metansulfonato de sibutramina cristalino.
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
AR045330A1 (es) * 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
TWI339586B (en) * 2003-10-31 2011-04-01 Takeda Chemical Industries Ltd Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
MX2009002781A (es) 2006-09-15 2009-03-30 Reviva Pharmaceuticals Inc Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
WO2011003039A2 (en) 2009-07-02 2011-01-06 Dexcom, Inc. Analyte sensors and methods of manufacturing same
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
IN2014MN01407A (cg-RX-API-DMAC10.html) 2011-12-30 2015-07-03 Reviva Pharmaceuticals Inc
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
HUP9904026A2 (hu) 2000-05-28
HRP970505A2 (en) 1998-08-31
BR9711517A (pt) 1999-08-24
KR20000048501A (ko) 2000-07-25
TR199900618T2 (xx) 1999-06-21
PL332305A1 (en) 1999-08-30
BG64473B1 (bg) 2005-04-30
US6174925B1 (en) 2001-01-16
IL128850A0 (en) 2000-01-31
NO991358D0 (no) 1999-03-19
US6617360B1 (en) 2003-09-09
MY116150A (en) 2003-11-28
AU724488B2 (en) 2000-09-21
CA2266401C (en) 2007-01-30
ID18320A (id) 1998-03-26
GB9619757D0 (en) 1996-11-06
NO991358L (no) 1999-03-19
NZ334580A (en) 2000-09-29
RU2245709C2 (ru) 2005-02-10
US20040077730A1 (en) 2004-04-22
UA64726C2 (uk) 2004-03-15
CA2266401A1 (en) 1998-03-26
TW580385B (en) 2004-03-21
SK31999A3 (en) 1999-12-10
BG103277A (en) 2000-01-31
ZA978450B (en) 1999-03-19
JP2001503737A (ja) 2001-03-21
EP0927028A1 (en) 1999-07-07
WO1998011884A1 (en) 1998-03-26
IL128850A (en) 2003-07-31
AU4774097A (en) 1998-04-14
CZ93699A3 (cs) 1999-08-11
CN1237905A (zh) 1999-12-08

Similar Documents

Publication Publication Date Title
AU4774097A (en) Use of sibutramine analogues to prevent the development of diabetes
GB9713077D0 (en) Improvements relating to skin prickers
AU132780S (en) Watch body
ZA986020B (en) Skin pricker
GB9708512D0 (en) Improvements relating to skin prickers
SG50831A1 (en) Fluorinated bitamin d3 analogs
GB2341180A9 (en) Compounds on the basis of polyalkyl-1-oxa diazaspirodecane compounds
ZA981419B (en) Arylsulfonamides and analogues
GB9727518D0 (en) Use
PL320923A1 (en) Graphite guide-rings
GB9404791D0 (en) Third body frictioning
ZA200304047B (en) Analogues of GLP-1.
GB2331742B (en) Monitoring the addition of a liquid agent to another liquid
GB9912318D0 (en) The use of staurosporine analogues for enhancing neutrophin activity
TW304478U (en) Pen structure of the finger-guessing game
SI0973511T1 (en) Use of sibutramine analogues to lower lipid levels
GB2332494B (en) Improvements relating to resilient mountings
TW327317U (en) Handle set with function of fastening
TW380680U (en) Improved structure of the revolving-horse-lamp
TW391368U (en) Structure of elastic synthetic leather
TW323508U (en) Improved structure of functional hand
GB9706855D0 (en) Wristwatch
HU9700738D0 (en) Functional watch
GB9726315D0 (en) Improvements relating to baths
GB9723508D0 (en) Novel use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees